https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54840 Wed 29 May 2024 11:39:57 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45172 Wed 26 Oct 2022 14:18:41 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45117 Wed 26 Oct 2022 12:45:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49760 Tue 30 May 2023 18:39:10 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45298 6 million deaths globally at the time of writing. COVID-19, instigated by the SARS - coronavirus-2 (SARS-CoV-2), causes unprecedented challenges in all facets of our lives, and never before brought scientists of all fields together to focus on this singular topic. While for the past 50 years research have been heavily focused on viruses themselves, we now understand that the host immune responses are just as important in determining the pathogenesis and outcomes of infection. Research in innate immune mechanisms is crucial in understanding all aspects of host antiviral programmes and the mechanisms underpinning virus-host interactions, which can be translated to the development of effective therapeutic avenues. This review summarizes what is known and what remains to be explored in the innate immune responses to influenza viruses and SARS-CoVs, and virus-host interactions in driving disease pathogenesis. This hopefully will encourage discussions and research on the unanswered questions, new paradigms, and antiviral strategies against these emerging infectious pathogens before the next pandemic occurs.]]> Tue 23 May 2023 08:41:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38714 Tue 18 Jan 2022 15:19:16 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45550 Tue 01 Nov 2022 10:56:22 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45207 Rhodiola wallichiana var. cholaensis (RWC) has the potential to alleviate asthmatic inflammation according to recent studies, but its pharmacological mechanisms remain unclarified. In our study, murine asthmatic phenotypes were established and treated with RWC and/or dexamethasone (DEX). Combined treatment with RWC and DEX could improve spirometry and airway hyperresponsiveness (AHR) in asthmatic phenotypes, alleviate steroid resistance in NEA, and reduce the inflammatory infiltration of the both phenotypes. The combined treatment increased Th1, regulated the imbalance of Th2/Th1, and decreased the related cytokines in EA. As for NEA, the combined treatment reduced Th17 and promoted the accumulation of regulatory T cells (Tregs) in lung. A microbiome study based on 16S rDNA sequencing technique revealed the significantly changed structure of the lower airway microbiota after combined treatment in NEA, with 4 distinct genera and 2 species identified. OPLS-DA models of metabolomics analysis based on UPLC-Q/TOF-MS technique identified 34 differentiated metabolites and 8 perturbed metabolic pathways. A joint multiomics study predicted that the colonized microbiota in airways might be associated with susceptibility of asthma and steroid resistance, which involved systematic and pulmonary metabolic perturbation. In summary, the pharmacological network of RWC included the complicated interaction mechanisms of immune regulation, microbiota change, and metabolic perturbation.]]> Thu 27 Oct 2022 15:07:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45231 Thu 27 Oct 2022 12:56:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43373 Thu 15 Sep 2022 15:46:34 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13324 Sat 24 Mar 2018 08:17:00 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17439 Sat 24 Mar 2018 08:01:35 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22085 Sat 24 Mar 2018 07:15:16 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38317 via esterification. Among them, compounds 2e (IC₅₀ =105 nM) and 3b (IC₅₀ =114 nM) displayed excellent ACE inhibitory activity in vitro, and exhibited non-toxic to H9c2 cells. The interactions between ACE and compounds were predicted by molecular docking respectively. In verapamil-induced zebrafish HF model, the activity assay showed that these two derivatives could improve cardiovascular physiological indexes including heart beats, venous congestion, heart dilation, cardiac output, ejection fraction and fractional shortening in a dose-dependent manner. A UPLC-QTOF-MS-based serum metabolomics approach was applied to explore the latent mechanism. A total of 25 differentiated metabolites and 8 perturbed metabolic pathways were identified. These results indicated that pyxinol fatty acid ester derivatives 2e and 3b might be considered as potent drug candidates against heart failure and deserved further research and development.]]> Mon 29 Jan 2024 18:52:01 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35951 Mon 20 Jan 2020 13:33:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46961 Mon 12 Dec 2022 12:42:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48813 Fri 14 Apr 2023 15:58:29 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47306 Fri 13 Jan 2023 10:52:32 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55971 Fri 12 Jul 2024 14:30:43 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51551 Fri 08 Sep 2023 15:06:19 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49776 Fri 02 Jun 2023 17:29:57 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40000 Fri 01 Jul 2022 14:31:38 AEST ]]>